Can MDMA Play a Role in the Treatment of Substance Abuse?
This review (2013) evaluates the potential of MDMA to treat substance abuse and dependence. The authors provide evidence that MDMA may have potential as a treatment for these morbidities but also highlight that classical psychedelics have a better risk to benefit ratio.
Authors
- Berra Yazar-Klosinski
- Lisa Jerome
Published
Abstract
A wider array of treatments are needed for people with substance abuse disorders. Some psychedelic compounds have been assessed as potential substance abuse treatments with promising results. MDMA may also help treat substance abuse based on shared features with psychedelic compounds and recent reports indicating that MDMAassisted psychotherapy can reduce symptoms of PTSD. Narrative reports and data from early investigations found that some people reduced or eliminated their substance use after receiving MDMA, especially in a therapeutic setting. MDMA is a potent monoamine releaser with sympathomimetic effects that may indirectly activate 5-HT2A receptors. It increases interpersonal closeness and prosocial feelings, potentially through oxytocin release. Findings suggest that ecstasy, material represented as containing MDMA, is associated with deleterious long-term effects after heavy lifetime use, including fewer serotonin transporter sites and impaired verbal memory. Animal and human studies demonstrate moderate abuse liability for MDMA, and this effect may be of most concern to those treating substance abuse disorders. However, subjects who received MDMA-assisted psychotherapy in two recent clinical studies were not motivated to seek out ecstasy, and tested negative in random drug tests during follow-up in one study. MDMA could either directly treat neuropharmacological abnormalities associated with addiction, or it could indirectly assist with the therapeutic process or reduce symptoms of comorbid psychiatric conditions, providing a greater opportunity to address problematic substance use. Studies directly testing MDMA-assisted psychotherapy in people with active substance abuse disorder may be warranted.
Research Summary of 'Can MDMA Play a Role in the Treatment of Substance Abuse?'
Introduction
Substance dependence and abuse remain a major public-health problem in the United States, with the extracted text citing an estimated 8.9% of Americans aged 12 or older reporting illicit drug use in the past month and 23.1 million people aged 12 or older in need of treatment for a substance use disorder. Despite a variety of existing interventions—psychotherapies, pharmacotherapies (for substitution or to target neurobiology), self-help groups, detoxification and rehabilitation—many treatments are underused, have limited long-term effectiveness, and trial findings may not generalise well to real-world settings. Earlier psychiatric research from the 1950s onward examined classical psychedelics such as LSD for alcoholism, and a more recent meta-analysis of randomized, double-blind, controlled studies reported reduced alcohol use after a single LSD exposure, suggesting that psychedelic-assisted approaches warrant further exploration in addiction treatment. This paper asks whether 3,4-methylenedioxymethamphetamine (MDMA) might play a role in treating substance abuse. Motivated by MDMA’s pharmacology and recent reports that MDMA-assisted psychotherapy reduces post-traumatic stress disorder (PTSD) symptoms, Jerome and colleagues review the literature on MDMA’s psychotherapeutic use, physiological and subjective effects, risks, and any available evidence—anecdotal or empirical—relating to changes in substance use. The goal is to assess whether MDMA could plausibly assist in treating addictive behaviours directly via neuropharmacology or indirectly by addressing comorbid psychiatric conditions and psychotherapeutic processes.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- Authors
- APA Citation
Jerome, L., Schuster, S., & Yazar-Klosinski, B. (2013). Can MDMA Play a Role in the Treatment of Substance Abuse?. Current Drug Abuse Reviews, 6(1), 54-62. https://doi.org/10.2174/18744737112059990005
References (14)
Papers cited by this study that are also in Blossom
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Mangini, M. · Journal of Psychoactive Drugs (2011)
Benzenhöfer, U., Passie, T. · Addiction (2010)
Greer, G. R. · Journal of Psychoactive Drugs (1986)
Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)
Bogenschutz, M. P., Pommy, J. A. · Drug Testing and Analysis (2012)
Liechti, M. E., Baumann, C., Gamma, A. et al. · Neuropsychopharmacology (2000)
Kuypers, K. P. C., Theunissen, E. L., Bosker, W. M. et al. · Neuropsychopharmacology (2011)
Liechti, M. E., Gamma, A., Vollenweider, F. X. · Psychopharmacology (2001)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Show all 14 referencesShow fewer
Bedi, G., Hyman, D., De Wit, H. · Biological Psychiatry (2010)
Kuypers, K. P. C., Ramaekers, J. G. · Journal of Psychopharmacology (2005)
Kuypers, K. P. C., Ramaekers, J. G. · Psychopharmacology (2006)
Halpern, J. H., Sherwood, A. R., Hudson, J. I. et al. · Addiction (2011)
Cited By (8)
Papers in Blossom that reference this study
Henningfield, J. E., Coe, M. A., Griffiths, R. R. et al. · Neuropharmacology (2022)
Sessa, B., Higbed, L., Durant, C. et al. · Journal of Psychopharmacology (2021)
DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)
Sessa, B., Sakal, C., O'Brien S. et al. · BMJ Case Reports (2019)
Dunlap, L. E., Andrews, A. M. · ACS Chemical Neuroscience (2018)
Phelps, J. · Journal of Humanistic Psychology (2017)
Sessa, B. · Neuroscience Letters (2016)
Winkelman, M. J. · Current Drug Abuse Reviews (2014)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.